Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Bio SB, a molecular pathology company based in Santa Barbara, Calif., has announced that it will partner with Cancer Diagnostics Inc. to distribute the Bio SB line of IHC antibodies, chromogens, and ancillaries in the U.S. market.
Biosearch Technologies, a supplier of oligonucleotide components to the rapidly growing molecular diagnostics industry, announced that it has acquired worldwide rights to TurboFISH technology, a method for rapid single molecule RNA FISH. With the TurboFISH license, Biosearch maintains exclusive access to continuing Stellaris RNA FISH-based inventions from Rutgers, The State University of New Jersey.
TriLink BioTechnologies, a provider of custom nucleic acid-based products, announced the launch of MitoPrimers, dilute-and-go primers for mitochondrial DNA PCR amplification and sequencing in forensic identification. The high sensitivity of mtDNA PCR amplification and sequencing allows forensic scientists to obtain information from evidence associated with homicides or other criminal investigations, body identifications, and cold cases, as well as small pieces of evidence containing little biological material.
Ventana Medical Systems announced the global launch of its BRAF V600E immunohistochemistry test to detect the BRAF V600E mutation in a variety of tumors. The test, launched as a U.S. class I exempt/CE-IVD product, is designed to detect the most frequent BRAF mutation, V600E, which has been found to play a key role in a variety of cancers, including colorectal cancer.
Diagnovus, a molecular diagnostics company focused on underserved, aggressive, and lesser-known diseases, announced the launch of the Engauge GI Barrett’s Esophagus genomic assay to predict the risk of progression to high-grade dysplasia or esophageal adenocarcinoma in Barrett’s esophagus patients.
Denville Scientific’s new Ultra EZpette high-precision digital pipettors provide accurate and precise liquid dispensing in an ergonomic design.
Horizon Discovery has signed a research service agreement with Blueprint Medicines, a patient-driven oncology company developing highly selective kinase inhibitors for genomically defined cancer subsets. Under the terms of the deal, Horizon will support Blueprint’s New Targets discovery platform by deploying its X-Man isogenic cell lines.
Beckman Coulter Life Sciences has received 510(k) clearance from the FDA and an import medical device registration certificate from the China Food and Drug Administration for the in vitro diagnostic use of the Navios flow cytometry system.
Audit MicroControls has added Control LQ Spinal Fluid to its line of daily quality control products. This bi-level reference control consisting of human serum-based solutions simulates patient spinal fluid samples for monitoring the precision of laboratory testing procedures for chloride, glucose, IgA, IgG, IgM, lactate, LDH, microalbumin, microprotein, and sodium.
Haemtech Biopharma Services announced the successful validation of a thrombin generation assay for an intravenous immunoglobulin drug. The assay was validated in 2012 to support the use of TGA as a release assay for Biotest Pharmaceuticals’ FDA biologics license application for BIVIGAM, an immune globulin intravenous (human), 10 percent liquid product. The validated TGA assay was designed and performed on the Calibrated Automated Thrombogram platform from Diagnostica Stago.
